17.58 USD
▲-0.23+1.88%
盘后 17.88 0.00%
2026-08-03
市值
$38.60M
市盈率
—
EPS
-7.57
股息率
—
52 周区间
3.66 – 42.12
成交量
4.08K
Beta
1.44
目标价
—
52W 低 3.6652W 高 42.12
价格走势
公司简介
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in...